Kidney cancer. Principles and practice. Second edition. Primo N. Lara, Jr. Eric Jonasch (Editors). Springer International Publishing (2015)

  1. American Cancer Society (2014) Cancer facts and figures 2014. American Cancer Society, Atlanta
  2. Linehan WM et al (2009) Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115(10 Suppl):2252–2261
  3. Liu H, Sundquist J, Hemminki K (2011) Familial renal cell carcinoma from the Swedish Family-Cancer Database. Eur Urol 60(5):987–993
  4. Shuch B et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32(5): 431–437
  5. Linehan WM, Ricketts CJ (2013) The metabolic basis of kidney cancer. Semin Cancer Biol 23(1):46–55
  6. Reaume MN et al (2013) Canadian guideline on genetic screening for hereditary renal cell cancers. Can Urol Assoc J 7(9–10):319–323
  7. Nickerson ML et al (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14(15):4726–4734
  8. Tory K et al (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81(14):1097–1101
  9. Hosoe S et al (1990) Localization of the von HippelLindau disease gene to a small region of chromosome 3. Genomics 8(4):634–640
  10. Latif F et al (1993) Identification of the von HippelLindau disease tumor suppressor gene. Science 260(5112):1317–1320
  11. Lonser RR et al (2003) von Hippel-Lindau disease. Lancet 361(9374):2059–2067
  12. Poston CD et al (1995) Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153(1): 22–26
  13. Neumann HP et al (1998) Prevalence, morphology and biology of renal cell carcinoma in von HippelLindau disease compared to sporadic renal cell carcinoma. J Urol 160(4):1248–1254
  14. Chen F et al (1995) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5(1):66–75
  15. McNeill A et al (2009) Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet A 149A(10):2147–2151
  16. Zbar B et al (1994) Hereditary papillary renal cell carcinoma. J Urol 151(3):561–566
  17. Zbar B et al (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153(3 Pt 2):907–912
  18. Schmidt L et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 16(1):68–73
  19. Bottaro DP et al (1991) Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 251(4995):802–804
  20. Zhuang Z et al (1998) Trisomy 7-harbouring nonrandom duplication of the mutant MEt allele in hereditary papillary renal carcinomas. Nat Genet 20(1):66–69
  21. Schmidt L et al (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18(14):2343–2350
  22. Schmidt L et al (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58(8):1719–1722
  23. Schmidt LS et al (2004) Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 172(4 Pt 1):1256–1261
  24. Lubensky IA et al (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155(2): 517–526
  25. Ornstein DK et al (2000) Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol 163(2):431–433
  26. Kloepfer HW et al (1958) Hereditary multiple leiomyoma of the skin. Am J Hum Genet 10(1):48–52
  27. Launonen V et al (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98(6):3387–3392
  28. Merino MJ et al (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31(10):1578–1585
  29. Reed WB, Walker R, Horowitz R (1973) Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 53(5):409–416
  30. Alam NA et al (2001) Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 68(5):1264–1269
  31. Tomlinson IP et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30(4):406–410
  32. Isaacs JS et al (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8(2):143–153
  33. Vanharanta S et al (2006) Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet 15(1):97–103
  34. Grubb RL 3rd et al (2007) Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 177(6):2074–2079; discussion 2079–2080
  35. Menko FH et al (2014) Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 13:637–644
  36. Shuch B et al (2013) Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. J Urol 189(2):430–435
  37. Srigley JR et al (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37(10): 1469–1489
  38. Birt AR, Hogg GR, Dube WJ (1977) Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113(12):1674–1677
  39. Schmidt LS et al (2001) Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69(4):876–882
  40. Baba M et al (2006) Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 103(42):15552–15557
  41. Nickerson ML et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the BirtHogg-Dube syndrome. Cancer Cell 2(2):157–164
  42. Hasumi Y et al (2009) Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 106(44): 18722–18727
  43. Zbar B et al (2002) Risk of renal and colonic neoplasms and spontaneous pneumothorax in the BirtHogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 11(4):393–400
  44. Roth JS et al (1993) Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 29(6):1055–1056
  45. Schmidt LS et al (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76(6):1023–1033
  46. Toro JR et al (1999) Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 135(10):1195–1202
  47. Pavlovich CP et al (2002) Renal tumors in the BirtHogg-Dube syndrome. Am J Surg Pathol 26(12): 1542–1552
  48. Pavlovich CP et al (2005) Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173(5):1482–1486
  49. Shuch B et al (2014) The genetic basis of pheochromocytoma and paraganglioma: implications for management. Urology 83(6):1225–1232
  50. Selak MA et al (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7(1):77–85
  51. Neumann HP et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8):943–951
  52. Ricketts C et al (2008) Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100(17):1260–1262
  53. Janeway KA et al (2011) Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 108(1):314–318
  54. European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75(7):1305–1315
  55. van Slegtenhorst M et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277(5327):805–808
  56. Kenerson HL et al (2002) Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62(20):5645–5650
  57. Liu MY, Poellinger L, Walker CL (2003) Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 63(10):2675–2680
  58. Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355(13):1345–1356
  59. Bjornsson J et al (1996) Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 149(4):1201–1208
  60. Nelen MR et al (1999) Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 7(3):267–273
  61. Liaw D et al (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16(1):64–67
  62. Nelen MR et al (1996) Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 13(1):114–116
  63. Headington JT, French AJ (1962) Primary neoplasms of the hair follicle. Histogenesis and classification. Arch Dermatol 86:430–441
  64. Tan MH et al (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18(2):400–407
  65. Shuch B et al (2013) Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol 190(6):1990–1998
  66. Woodward ER et al (2010) Population-based survey of cancer risks in chromosome 3 translocation carriers. Genes Chromosomes Cancer 49(1):52–58
  67. Kanayama H et al (2001) Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma. J Med Genet 38(3):165–170
  68. Schmidt L et al (1995) Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am 1(3):191–195
  69. Alanen KA et al (1984) Renal oncocytoma: the incidence of 18 surgical and 12 autopsy cases. Histopathology 8(5):731–737
  70. Dechet CB et al (1999) Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol 162(1):40–42
  71. Perez-Ordonez B et al (1997) Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol 21(8):871–883
  72. Weirich G et al (1998) Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 160(2): 335–340
  73. Tickoo SK et al (1999) Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol 23(9):1094–1101
  74. Clark JE (1970) Transplantation for bilateral renal tumors. JAMA 211(8):1379
  75. Jochimsen PR, Braunstein PM, Najarian JS (1969) Renal allotransplantation for bilateral renal tumors. JAMA 210(9):1721–1724
  76. Bratslavsky G, Linehan WM (2010) Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol 7(5):267–275
  77. Carini M et al (2006) Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol 50(6):1263–1268; discussion 1269–1271
  78. Goldfarb DA et al (1997) Results of renal transplantation in patients with renal cell carcinoma and von HippelLindau disease. Transplantation 64(12):1726–1729
  79. Herring JC et al (2001) Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 165(3):777–781
  80. Ricketts CJ et al (2012) Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 188(6):2063–2071
  81. Shuch B et al (2014) Adverse health outcomes associated with surgical management of the small renal mass. J Urol 191(2):301–309


[contact-form-7 id=»5168″ title=»Контактная форма 1″]


Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *